ESMO HIGHLIGHTS 2023 - MELANOMA ROUNDTABLE DISCUSSION - OncologyEducation

ESMO HIGHLIGHTS 2023 – MELANOMA ROUNDTABLE DISCUSSION

Chair

Dr. Teresa Petrella

Panelist

Dr. Marcus Butler
Prof. Caroline Robert

Podcasts

2023

ESMO HIGHLIGHTS 2023 – MELANOMA ROUNDTABLE DISCUSSION: SECOMBIT trial

2023

ESMO HIGHLIGHTS 2023 – MELANOMA ROUNDTABLE DISCUSSION: Phase III NIBIT-M2 trial

2023

ESMO HIGHLIGHTS 2023 – MELANOMA ROUNDTABLE DISCUSSION: TACo in pts with PD1 refractory MBM

2023

ESMO HIGHLIGHTS 2023 – MELANOMA ROUNDTABLE DISCUSSION: IT and IV N for MM pts with LMD

2023

ESMO HIGHLIGHTS 2023 – MELANOMA ROUNDTABLE DISCUSSION: SWOG S1801

2023

ESMO HIGHLIGHTS 2023 – MELANOMA ROUNDTABLE DISCUSSION: mRNA-4157

2023

ESMO HIGHLIGHTS 2023 – MELANOMA ROUNDTABLE DISCUSSION: Results from the phase 2 C-144-01 study

2023

ESMO HIGHLIGHTS 2023 – MELANOMA ROUNDTABLE DISCUSSION: A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV CSCC

2023

ESMO HIGHLIGHTS 2023 – MELANOMA ROUNDTABLE DISCUSSION: Three-year survival with tebentafusp

2023

ESMO HIGHLIGHTS 2023 – MELANOMA ROUNDTABLE DISCUSSION: ctDNA reduction daro + crizo combination in MUM

Tagged login-not-required stand-alone